Small RNA Binary Predictor Identification via Sequencing Analysis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The diagnostic potential of microRNAs and other small non-coding RNAs has not been fully realized despite their role in human disease, as existing methods focus on up- or down-regulated RNAs rather than identifying unique sequences present in specific cohorts.

Innovation Solution

A method for identifying small RNA predictors by sequencing data analysis, where sequences unique to an experimental cohort are identified and validated using PCR assays, allowing for the detection of binary predictors in biological samples.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If existing methods focus on up- or down-regulated RNAs, then regulatory changes can be detected, but unique sequences present in specific cohorts cannot be identified

Engineering Contradiction:
Improveability to identify unique sRNA sequencesVSAvoiddiagnostic potential across different disease cohorts
Core Design Contradiction:
Measurement precisionVSAdaptability or versatility

Solution Approach 1:

Instead of focusing on regulated RNAs as done conventionally, the patent inverts the approach by focusing on identifying unique sRNA sequences that are present in one cohort but absent in another. This inversion enables discovery of binary predictors with high diagnostic value rather than relying on expression level changes.

Inventive Principle:
Principle #13The other way round (Inversion)

Solution Approach 2:

The patent changes the detection parameter from expression level (up/down-regulation) to presence/absence of unique sequences. By quantifying reads for each unique sRNA sequence and comparing cohorts, the method identifies sequences that are binary predictors, fundamentally changing how diagnostic markers are discovered.

Inventive Principle:
Principle #35Parameter changes

2Measurement precision

If sRNA sequencing data is analyzed without trimming adaptors, then sequencing efficiency is maintained, but accurate identification of sRNA sequences at 3' and 5' ends cannot be achieved

Engineering Contradiction:
Improveaccuracy of sRNA sequence identificationVSAvoiddata processing complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by trimming user-defined sequencing adaptors from sequence reads before analysis. This preprocessing step enables accurate identification of templated and non-templated variations at the 3' and 5' ends of sRNA molecules, which is essential for precise sequence characterization.

Inventive Principle:
Principle #10Preliminary action

3Reliability

If small RNA predictors are identified using cohort comparison, then diagnostic specificity is improved, but sample size requirements increase

Engineering Contradiction:
Improvediagnostic specificity of sRNA predictorsVSAvoidnumber of samples required
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent extracts and focuses only on unique sRNA sequences that differentiate cohorts, discarding sequences common to both. By quantifying reads for each unique sequence and identifying binary predictors, the method achieves high diagnostic specificity while requiring manageable sample sizes (at least 10 per cohort).

Inventive Principle:
Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach unlocks the diagnostic utility of miRNAs and other sRNAs by identifying specific sequences predictive of conditions like neurodegenerative diseases, cardiovascular diseases, and cancers, enabling early diagnosis and differentiation among similar diseases.

Implementation Method 1

detecting the presence and absence of selected positive sRNA predictors in RNA extracted from independent experimental and comparator samples using a quantitative or qualitative PCR assay

Methodology Applied
Scientific EffectPCR amplification:

Data Source

PatentEP3571315B1Methods for identifying and using small RNA predictors
Publication Date: 2025.01.08 GATEHOUSE BIO INC
  • EP3571315B1 patent drawingFigure 1A~1B
  • EP3571315B1 patent drawingFigure 2
  • EP3571315B1 patent drawingFigure 3A~3B

AI summary

The invention provides a method for identifying or detecting small RNA (sRNA) predictors of a disease or a condition. The method comprises identifying one or more sRNA sequences that are present in one or more samples of an experimental cohort, and which are not present across a comparator cohort; and optionally identifying one or more sRNA sequences that are present in one or more samples of a comparator cohort, and which are not present across an experimental cohort. In contrast to identifying dysregulated non-coding RNAs (such as miRs that are up- or down-regulated), the invention identifies sRNAs that are binary predictors, that is, present in one cohort (e.g., an experimental cohort) and not another (e.g., a comparator cohort). Further, by quantifying reads for individual sequences (e.g., iso-miRs), without consolidating reads to annotated reference sequences, the invention unlocks the diagnostic utility of miRs and other sRNAs.